Tirzepatide

From Retapedia, the free peptide encyclopedia
"Tirzepatide" redirects here. For other uses, see Tirzepatide (disambiguation).
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Tirzepatide (also known as Tirzepatide or GIP/GLP-1 dual agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, diabetes. FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly as Mounjaro (type 2 diabetes, 2.5-15mg weekly) and Zepbound (obesity and obstructive sleep apnea, 2.5-15mg weekly). Unique imbalanced agonist with greater GIP receptor engagement than GLP-1, plus biased GLP-1 agonism favoring cAMP generation over β-arrestin recruitment, enhancing insulin secretion. SURMOUNT trials demonstrated exceptional weight loss: 20.9% at 72 weeks (15mg dose), with 50-57% of participants achieving ≥20% weight loss.

Natty status
Tirzepatide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Dosage and administration
  5. 5 Natty status
  6. 6 Research
  7. 7 Related compounds
  8. 8 References
  9. 9 External links

Overview

SURMOUNT-4 showed 25.3% mean weight reduction long-term.

Unprecedented diabetes efficacy in SURPASS trials with HbA1c reductions of 1.9-2.6% and weight loss of 6.6-13.9kg, superior to semaglutide 1mg.

December 2024 FDA approval as first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, reducing breathing disruptions by 25-29 per hour (5x more effective than placebo).

Cardiovascular meta-analysis showed HR 0.80 for MACE-4, with SURPASS-4 showing HR 0.50 at 15mg dose.

Common side effects are gastrointestinal (nausea, vomiting, diarrhea 16.24% vs 8.63% placebo), typically mild-to-moderate, transient, occurring during dose escalation. 2024 systematic review found no association with pancreatitis.

Gradual titration every 4 weeks (2.5mg steps) minimizes adverse events.

Available in 6 strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.

Mechanism of action

Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.

Reported effects

Effects reported in the literature and from preclinical models include:

  • Tirzepatide produced about 14.9% greater weight loss than lifestyle modification alone at one year, the largest reduction among 19 obesity drugs compared in a network meta-analysis of 262 randomized trials, and cut fat mass the most (25.7%). [9] Phase III
  • Tirzepatide lowers HbA1c and reduces body weight by 5-20.9% over 72 weeks in a dose- and duration-dependent way, by raising insulin secretion, lowering glucagon, delaying gastric emptying, and promoting satiety. [4][8] Phase II
  • In heart failure with preserved or mildly reduced ejection fraction, incretin therapies including tirzepatide cut heart failure hospitalizations and events (hazard ratio 0.68) and the composite of cardiovascular death or heart failure events (hazard ratio 0.76), irrespective of diabetes status. [5][7][3][1] Phase III
  • In obese patients with obstructive sleep apnea, dual GIP/GLP-1 receptor agonist therapy reduces the apnea-hypopnea index alongside weight loss and lowers cardiometabolic risk. [6] Phase II
  • Under standardized meal tests, GLP-1 and dual GIP/GLP-1 receptor agonist therapy reduced ad libitum lunch energy intake by about 271 kcal versus placebo. [10] Phase II
  • The main tolerability burden is gastrointestinal adverse events (risk ratio up to about 4.2 versus comparators) with a 4-10% treatment discontinuation rate, alongside the greatest lean-mass loss of any obesity drug at about 8.3%. [9][4][2] Phase III

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

⚠
Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

  • Week 1-4: 2.5mg once weekly (subcutaneous, starting dose)
  • Week 5-8: 5.0mg once weekly
  • Week 9-12: 7.5mg once weekly (optional step)
  • Week 13-16: 10mg once weekly
  • Week 17-20: 12.5mg once weekly (optional step)
  • Week 21+: 15mg once weekly (maximum dose)
  • Escalate by 2.5mg every 4 weeks minimum
  • Do not increase faster than 2.5mg per 4 weeks

Maintenance

  • 5mg, 10mg, or 15mg based on response/tolerability

Available strengths

  • 2.5, 5, 7.5, 10, 12.5, 15mg per 0.5mL

Natty status

See also: Peptide § Natty status

Tirzepatide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[11]

Research

127 active clinical trials on record — highest phase: Phase 4
View on ClinicalTrials.gov · fetched Aug 4, 2026

The peptide has been the subject of 38 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Ozempic Natty
Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
Retatrutide Not natty
Triple agonist that curbs appetite and raises energy expenditure for 24% weight loss. Improves blood sugar, lowers blood pressure, and normalizes liver fat. Investigational; not FDA-approved.
mots-c Not natty
Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.
5-Amino-1MQ Not natty
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.

References

  1. ^ [Glucagon-like peptide-1 agonists and heart failure]. Recent review
  2. ^ Tirzepatide data: safety always comes first! Recent review
  3. ^ GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review. Recent review
  4. a b Tirzepatide. Recent review
  5. ^ Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis. Recent review
  6. ^ [The role of obesity and weight reduction in obstructive sleep apnea]. Recent review
  7. ^ The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis. Recent review
  8. ^ Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. Recent review
  9. a b Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. Recent review
  10. ^ Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis. Recent review
  11. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Fat loss | Weight loss | Diabetes | Cardiovascular

This page was last updated on August 4, 2026, at 00:45 (UTC).

Research last reviewed on August 4, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.